Results 81 to 90 of about 92,725 (294)

Continuous renal replacement therapy for critically ill infants and children

open access: yes, 2012
Continuous renal replacement therapy (CRRT) is an important treatment in critically ill children with acute kidney injury (AKI). Over the past decade, CRRT has been the preferred method of renal replacement therapy. We compared children with CRRT-treated
Jepsen, Søren Bruun   +2 more
core   +1 more source

Effect of Continuous Renal Replacement Therapy on Outcome in Pediatric Acute Liver Failure*

open access: yes, 2016
Objectives: To establish the effect of continuous renal replacement therapy on outcome in pediatric acute liver failure.Design: Retrospective cohort study.Setting: Sixteen-bed PICU in a university-affiliated tertiary care hospital and specialist liver ...
Deep, Akash   +7 more
core   +1 more source

Inflammation Unchecked: Concurrent Kawasaki Disease and Stevens‐Johnson Syndrome in an 18‐Month‐Old Child

open access: yes
Arthritis Care &Research, EarlyView.
Catherine Deffendall   +6 more
wiley   +1 more source

Autoimmune Encephalitis in Acute Care—Pathology, Diagnosis, and Management

open access: yesAdvanced Science, EarlyView.
ABSTRACT Autoimmune encephalitis (AE) is characterized by immune‐mediated inflammation of the brain parenchyma, presenting with various neurological syndromes, including but not limited to seizures, altered consciousness, neuropsychiatric symptoms, and movement disorders.
Suneesh Thilak   +9 more
wiley   +1 more source

A New Approach to Renal Replacement for Acute Renal Failure in the Intensive Care Unit: Sustained Low Efficiency Dialysis-Extended Daily Dialysis

open access: yesTurkish Journal of Nephrology, 2019
Continuous renal replacement therapies have advantages over intermittent hemodialysis in the treatment of critically ill patients with acute renal failure.
Aves Editorial Aves Editorial
doaj   +2 more sources

Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients

open access: yes, 2010
BACKGROUND The optimal intensity of continuous renal-replacement therapy remains unclear. We conducted a multicenter, randomized trial to compare the effect of this therapy, delivered at two different levels of intensity, on 90-day mortality among ...
Ostermann, Marlies, Chang, Rene W.
core   +1 more source

Combating VEGFA‐siRNA‐Induced Metabolic Reprogramming via Glucose Utilization Deprivation

open access: yesAdvanced Science, EarlyView.
An ionizable lipid nanoparticle co‐delivers VEGFA siRNA and glucose oxidase to tumors to counteract VEGFA knockdown‐induced, glutamine‐driven metabolic compensation. Enzymatic glucose consumption reverses the adaptive pathways and restores metabolism toward baseline, thereby sensitizing tumors to therapy.
Lulu Zheng   +10 more
wiley   +1 more source

Meropenem Continuous Infusion in a Septic Patient with Periprosthetic Infection and End-Stage Renal Disease Undergoing Prolonged Intermittent Renal Replacement Therapy

open access: yesMedicina
This case report highlights the use of continuous infusion of meropenem in a 42-year-old septic female patient with periprosthetic infection and end-stage renal disease receiving prolonged intermittent renal replacement therapy (PIRRT).
Assiya Kadralinova   +3 more
doaj   +1 more source

Basics of continuous renal replacement therapy in pediatrics

open access: yesKidney Research and Clinical Practice, 2019
In the last three decades, significant advances have been made in the care of children requiring renal replacement therapy (RRT). The move from the use of only hemodialysis and peritoneal dialysis to continuous venovenous hemofiltration with or without ...
Jacob C. John   +2 more
doaj   +1 more source

Complications with continuous renal replacement therapy

open access: yes, 1996
Continuous renal replacement therapies (CRRTs) are widely used as a treatment of acute renal failure (ARF) in critically ill patients. Because of the severe illness of these patients, it is sometimes difficult to distinguish between complications related
Ronco C, Bellomo R
core   +1 more source

Home - About - Disclaimer - Privacy